Your browser is no longer supported. Please, upgrade your browser.
AZN [NASD]
AstraZeneca PLC
Index- P/E93.22 EPS (ttm)0.63 Insider Own0.50% Shs Outstand2.99B Perf Week1.72%
Market Cap186.40B Forward P/E15.15 EPS next Y3.90 Insider Trans0.00% Shs Float2.60B Perf Month3.79%
Income1.47B PEG4.48 EPS next Q0.74 Inst Own17.40% Short Float0.24% Perf Quarter-3.46%
Sales32.82B P/S5.68 EPS this Y137.20% Inst Trans-0.00% Short Ratio1.34 Perf Half Y1.49%
Book/sh13.28 P/B4.45 EPS next Y21.12% ROA1.90% Target Price68.18 Perf Year10.99%
Cash/sh2.27 P/C26.07 EPS next 5Y20.80% ROE6.90% 52W Range46.48 - 64.21 Perf YTD1.46%
Dividend1.40 P/FCF137.46 EPS past 5Y1.70% ROI12.20% 52W High-7.96% Beta0.49
Dividend %2.37% Quick Ratio0.70 Sales past 5Y1.50% Gross Margin71.20% 52W Low27.15% ATR0.87
Employees76100 Current Ratio1.10 Sales Q/Q50.00% Oper. Margin8.60% RSI (14)56.66 Volatility1.44% 1.33%
OptionableYes Debt/Eq0.80 EPS Q/Q-323.80% Profit Margin4.50% Rel Volume1.23 Prev Close60.17
ShortableYes LT Debt/Eq0.73 EarningsFeb 10 BMO Payout217.40% Avg Volume4.63M Price59.10
Recom2.00 SMA201.47% SMA503.07% SMA2002.72% Volume5,677,688 Change-1.78%
Dec-07-21Downgrade Jefferies Buy → Hold
Aug-12-21Resumed JP Morgan Overweight
Apr-12-21Downgrade Argus Buy → Hold
Mar-16-21Upgrade Jefferies Hold → Buy
Feb-25-21Upgrade UBS Neutral → Buy
Jan-15-21Initiated Deutsche Bank Buy
Dec-07-20Upgrade Morgan Stanley Equal-Weight → Overweight
Nov-30-20Upgrade UBS Sell → Neutral
Nov-11-20Upgrade HSBC Securities Reduce → Hold
Sep-29-20Initiated Berenberg Buy
Nov-22-19Initiated SVB Leerink Outperform
Oct-25-19Upgrade Liberum Hold → Buy
Apr-02-19Downgrade UBS Neutral → Sell
Feb-05-19Initiated Exane BNP Paribas Outperform
Jan-25-19Upgrade Shore Capital Hold → Buy
Dec-11-18Resumed Jefferies Hold
Oct-09-18Initiated Guggenheim Buy
Aug-16-18Downgrade Jefferies Buy → Hold
Mar-19-18Upgrade Jefferies Hold → Buy
Feb-06-18Reiterated Leerink Partners Mkt Perform $36 → $38
Jan-21-22 05:38PM  
05:38PM  
03:47PM  
01:59PM  
01:47PM  
10:00AM  
05:33AM  
Jan-20-22 04:59PM  
03:43PM  
03:22PM  
10:04AM  
Jan-19-22 11:34PM  
04:03PM  
01:38PM  
12:50PM  
Jan-18-22 05:50PM  
05:20PM  
03:19PM  
10:34AM  
10:06AM  
Jan-17-22 07:41PM  
07:00AM  
Jan-14-22 02:12PM  
06:52AM  
Jan-13-22 07:14AM  
07:08AM  
07:08AM  
07:05AM  
07:00AM  
05:59AM  
03:07AM  
Jan-12-22 02:56PM  
01:50PM  
01:34PM  
11:39AM  
06:20AM  
Jan-11-22 04:33PM  
03:33PM  
10:03AM  
Jan-10-22 04:30PM  
04:30PM  
03:37PM  
02:52PM  
11:15AM  
Jan-08-22 06:40AM  
Jan-07-22 04:26PM  
11:25AM  
Jan-06-22 04:31PM  
10:59AM  
03:11AM  
Jan-05-22 04:22PM  
02:03PM  
Jan-04-22 04:35PM  
02:32PM  
02:26PM  
12:27PM  
11:56AM  
08:47AM  
Jan-03-22 04:52PM  
12:25PM  
12:05PM  
11:39AM  
07:25AM  
Jan-01-22 06:55AM  
Dec-31-21 01:47PM  
Dec-30-21 06:15PM  
10:07AM  
09:27AM  
Dec-29-21 04:56PM  
02:00PM  
11:59AM  
11:41AM  
10:22AM  
Dec-28-21 05:08PM  
05:00PM  
07:00AM  
04:54AM  
Dec-27-21 11:38PM  
11:38PM  
08:38PM  
04:58PM  
Dec-24-21 06:00PM  
11:00AM  
09:13AM  
07:38AM  
Dec-23-21 06:15PM  
05:38PM  
05:00PM  
02:38PM  
12:34PM  
12:18PM  
11:30AM  
10:49AM  
09:30AM  
07:00AM  
06:47AM  
05:15AM  
04:20AM  
03:49AM  
02:41AM  
AstraZeneca PLC discovers, develops, manufactures, and commercializes prescription medicines in the areas of oncology, cardiovascular, renal and metabolism, respiratory, infection, neuroscience, and gastroenterology worldwide. The company's marketed products include Tagrisso, Lynparza, Imfinzi, Enhertu, Koselugo, Lumoxiti, Equidacent, Zoladex, Faslodex, Iressa, Arimidex, Casodex/Cosudex, and others for oncology diseases; Onglyza, Bydureon, Lokelma, Byetta, Qtern, Symlin, and others for cardiovascular, renal, and metabolism diseases; and Symbicort, Pulmicort, Fasenra, Daliresp/Daxas, Duaklir, Tudorza/Eklira, Bevespi, Breztri, Anifrolumab, and others for respiratory and immunology diseases. It also offers other medicines and COVID-19 products, including Synagis, Fluenz Tetra/FluMist Quadrivalent, Seroquel IR/Seroquel XR, Vimovo, Movantik/Moventig, Nexium, Losec/Prilosec, and COVID-19 Vaccine AstraZeneca. The company serves primary care and specialty care physicians through distributors and local representative offices. It has a collaboration agreement with Daiichi Sankyo to develop and commercialize DS-1062 for the treatment of trophoblast cell-surface antigen 2 (TROP2) tumor; AliveCor, Inc. to develop non-invasive potassium monitoring solutions; Massachusetts General Hospital to accelerate digital health solutions; Sanguina on smartphone application study for hemoglobin management in patients with anemia of chronic kidney disease; Alchemab to enhance prostate cancer research; and Proteros biostructures GmbH to discover and develop novel small molecules. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. It has a collaboration agreement with Regeneron Pharmaceuticals, Inc. to research, develop, and commercialize small molecule medicines for obesity; and Neurimmune AG to develop and commercialize NI006. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom.